Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Not-So-Quick Fix: ADHD Behavioral Therapy May Be More Effective Than Drugs, Says Child Development Institute.

 



(Medical-NewsWire.com, June 06, 2012 ) Orange, CA -- The recent article was based on findings of the April 2012 Experimental Biology meeting held in San Diego. At the conclusion of the meeting a consensus opinion was formed based on a new synthesis of behavioral, cognitive and pharmacological findings. According to Scientific American summary, the basic conclusion was:



“Behavioral and cognitive therapies focused on reducing impulsivity and reinforcing positive long-term habits may be able to replace current high doses of stimulant treatment in children and young adults”.



However, this does not mean that all children, teens and adults with a diagnosis of ADHD can be successful in life without taking any medication. The conclusion instead suggests that a combination of lower doses of medication combined with behavioral and cognitive therapy may produce better long-term benefits than medication alone.



In fact, independent research and current professional guidelines for the treatment of ADHD in children suggest that individuals with mild to moderate symptoms should be started on psychological treatment first with medication added only if needed after an adequate trial on the behavioral and cognitive interventions.



The article ends with a note of caution:



“The trick will be identifying which of the new therapies is most effective, and making those therapies affordable. For now, stimulant medications are much cheaper and act faster than behavioral therapy, even if the latter may be the most effective in the long run. But experts as well as parents know that the long run is what matters most.”



One possible solution that thousands of parents have turned to is Total Focus - a comprehensive, multimedia, home-use treatment program using behavioral and cognitive interventions that have been found to be effective by scientific research.



The program was developed by child psychologist Robert Myers and is based on a successful outpatient group treatment program developed for a regional health plan in California.



After a thorough review of the program, a recognized ADHD researcher concluded, “In a nutshell, I am most impressed with this program, which incorporates a wealth of extremely helpful information and programming, derived largely from evidence-based practice presented in an extremely user-friendly format for the families of children with Attention Deficit Disorder (ADD)”.



The program costs less than one visit to a mental health professional or around two months on many common ADHD medications.



The ADD behavioral program provides parent education, a behavior modification program, cognitive behavioral therapy, relaxation-biofeedback training, social skills training and brain training (cognitive rehabilitation exercises) and many other useful resources.



It ensures that Parents and children work as a team to produce positive changes in behavior at home and at school, as well as achieve improved academic potential.



More information about the Total Focus ADD Behavioral Program can be found here.





******

About Total Focus:



Total Focus is a multi-media program that provides what health professionals refer to as Evidence-based Treatment (based on scientific research).



The program is delivered via a CD with an interactive workbook, daily success charts for teachers and a handy “stress meter” to help every child recognize when he’s “over the top” and stay calm under stress. The program works with both parents and their children.



Both the American Academy of Pediatrics (AAP) and the American Academy of Child & Adolescent Psychiatry (AACAP) professional guidelines for best practice treatment of ADHD / ADD state that medication should be used in conjunction with psychological interventions for best over-all results.



The guidelines also state that for children with mild to moderate ADHD symptoms, it may be advisable to try psychological interventions first before adding medication.



Total Focus

Robert Myers, PHD

robertm@childdevelop

info@10acne.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo News
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on top health stories.

Prepackaged caramel apples linked to 4 deaths
19 Dec 2014 at 5:52pm
WASHINGTON (AP) ? Health officials are warning consumers to avoid prepackaged caramel apples because they are linked to four deaths and more than two dozen illnesses in 10 states.

FDA approves AbbVie combo hepatitis C treatment
19 Dec 2014 at 5:32pm
TRENTON, N.J. (AP) ? Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie.

U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks
19 Dec 2014 at 5:02pm
By Caroline Humer (Reuters) - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Solvadi from Gilead Sciences. Gilead's Sovaldi treatment stole headlines last year with its $84,000 price tag and set off a national debate about whether drug prices have climbed too high. AbbVie's newly approved regimen is also less costly than Gilead's newest one-pill regimen that combines Sovaldi with another drug and costs $94,500 for 12 weeks. ...


U.N. chief praises Ebola nurses, pledges support during visit
19 Dec 2014 at 4:43pm

By Matthew Mpoke Bigg HASTINGS, Sierra Leone (Reuters) - U.N. Secretary General Ban Ki-moon on Friday praised healthcare workers fighting the Ebola virus as he paid his first visit to Liberia and Sierra Leone following an outbreak that has killed nearly 7,000 people. Ban paid tribute to local workers and the United Nations, but he singled out medics from the three countries at the heart of the epidemic who have fallen sick while treating patients. ...



Coal ash is not hazardous waste under U.S. agency rules
19 Dec 2014 at 4:02pm

By Jonathan Kaminsky (Reuters) - In a disappointment to environmentalists, the U.S. Environmental Protection Agency issued rules on Friday labeling coal ash, a byproduct of coal-based power production containing toxic materials such as arsenic and lead, as non-hazardous waste. The label means that states and environmental groups taking legal action, and not the EPA, will be the primary enforcers of the first-ever federal rules targeting coal ash, which will require the closure of some coal ash holding ponds leaking contaminants into surrounding water but will not cover others. ...


Child being observed at Chicago hospital to rule out Ebola
19 Dec 2014 at 3:49pm
By Mary Wisniewski CHICAGO (Reuters) - A child who arrived in Chicago with a fever was under observation on Friday at a city hospital to rule out the Ebola virus, hospital officials said. Federal officials screening arriving passengers at O'Hare International Airport detected the fever, but no other symptoms of the disease, the University of Chicago Medical Center said in a statement. The patient was isolated under strict quarantine protocols until the child?s condition improves and a diagnosis is established, the hospital said. The child was in stable condition. ...

AbbVie says newly approved hepatitis C treatment costs $83,319
19 Dec 2014 at 3:47pm
(Reuters) - An AbbVie Inc spokeswoman on Friday said that the company's newly approved hepatitis C treatment will cost $83,319 for a 12-week course, coming in a bit below the price of competing treatments from Gilead Sciences Inc. U.S. health regulators earlier on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead. (Reporting by Caroline Humer)

FDA approves Cubists' drug for antibiotic-resistant bacteria
19 Dec 2014 at 3:12pm
By Amrutha Penumudi and Rosmi Shaji (Reuters) - Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs. Cubist shares were up 1.9 percent in extended trading. The drug, Zerbaxa, treats infections caused by gram-negative bacteria ? a type of antibiotic-resistant pathogens, often called superbugs. ...


Husbands Sign Up To Support Wives In Safe Motherhood Program in Uganda
19 Dec 2014 at 2:55pm

George Lwigala has probably never heard of HeForShe nor indeed of Emma Watson. But the 36-year-old father, who lives in Butansi in rural Uganda, embodies the spirit of the gender equality campaign launched by the actress in New York in September.George has five children with his wife Annette, who recently joined a Safe Motherhood and Maternal...


Oklahoma to again employ injection mix used in flawed execution
19 Dec 2014 at 2:48pm
By Heide Brandes OKLAHOMA CITY (Reuters) - Oklahoma plans to use the same lethal injection drug combination it employed during a botched execution in April, Department of Corrections officials told a federal court hearing arguments on whether to halt death sentences in the state from being carried out. Lawyers for 21 death row inmates in Oklahoma, four of whom are scheduled to die next year, have asked the court to suspend future executions following the lethal injection of convicted murderer Clayton Lockett. ...

USDA report says pesticide residues in food nothing to fear
19 Dec 2014 at 2:27pm
By Carey Gillam (Reuters) - More than half of food tested by the U.S. government for pesticide residues last year showed detectable levels of pesticides, though most were within levels the government considers to be safe, according to a report issued Friday by the U.S. Department of Agriculture. The USDA looked at fresh and processed fruits and vegetables as well as infant formula, apple juice, and other products. ...


Parents of Colorado theater gunman plead for son?s life to be spared
19 Dec 2014 at 2:20pm

By Keith Coffman DENVER (Reuters) - The parents of the man charged in the fatal shootings of 12 people at a Colorado movie theater broke their silence over the 2012 killings on Friday, saying their son is mentally ill, "not a monster," and should be spared the death penalty. Arlene and Robert Holmes urged prosecutors to accept a guilty plea from their son, James Holmes, and a life sentence without parole to avoid the ?additional trauma? that a lengthy trial would inflict on survivors and victims' families. ...


Missouri school regrets swapping blind student's cane for foam tube
19 Dec 2014 at 2:05pm
(Reuters) - A Missouri school district has apologized for taking a cane away from a blind student and forcing him to use a foam tube called a pool noodle, the boy's father said on Friday. Earlier this week, North Kansas School District confiscated the cane of 8-year-old Dakota Nafzinger, who was born without eyes, after he reportedly swung it on a bus. A teacher gave the boy the foam tube instead, said his father Don Nafzinger. The school district, which serves more than 19,000 students in Kansas City, Missouri, said in a statement it made a mistake. ...


Wall Street up for third day, led by energy shares
19 Dec 2014 at 2:02pm

NEW YORK (Reuters) - U.S. stocks extended gains for a third session on Friday, giving the S&P 500 its best weekly performance in nearly two months as energy shares continued to rebound.


Conjoined Twin Babies Undergo First Step Toward Separation
19 Dec 2014 at 1:45pm
Knatalye and Adeline Mata underwent a 5-hour skin-stretching surgery.

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC